INTRODUCTION
Gliomas are classified according to the 2016 Central Nervous System World Health Organization (WHO) criteria based on histopathologic and molecular features. 1 Because of the heterogeneity of gliomas, grading may be limited by sampling errors, and does not always predict the biologic behavior of the tumor or the patients' prognosis.
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-BACKGROUND: Structural magnetic resonance imaging (MRI) and histopathologic tissue sampling are routinely performed as part of the diagnostic workup for patients with glioma. Because of the heterogeneous nature of gliomas, there is a risk of undergrading caused by histopathologic sampling errors. MRI has limitations in identifying tumor grade and type, detecting diffuse invasive growth, and separating recurrences from treatment induced changes. Positron emission tomography (PET) can provide quantitative information of cellular activity and metabolism, and may therefore complement MRI. In this report, we present the first patient with brain glioma examined with simultaneous PET/MRI using the amino acid tracer 18 F-fluciclovine ( 18 F-FACBC) for intraoperative image-guided surgery.
-CASE DESCRIPTION: A previously healthy 60-year old woman was admitted to the emergency care with speech difficulties and a mild left-sided hemiparesis. MRI revealed a tumor that was suggestive of glioma. Before surgery, the patient underwent a simultaneous PET/MRI examination. Fused PET/MRI, T1, FLAIR, and intraoperative three-dimensional ultrasound images were used to guide histopathologic tissue sampling and surgical resection. Navigated, imageguided histopathologic samples were compared with PET/MRI image data to assess the additional value of the PET acquisition. Histopathologic analysis showed anaplastic oligodendroglioma in the most malignant parts of the tumor, while several regions were World Health Organization (WHO) grade II.
-CONCLUSIONS:
18 F-Fluciclovine uptake was found in parts of the tumor where regional WHO grade, cell proliferation, and cell densities were highest. This finding suggests that PET/MRI with this tracer could be used to improve accuracy in histopathologic tissue sampling and grading, and possibly for guiding treatments targeting the most malignant part of extensive and eloquent gliomas.
detection due to its high soft-tissue contrast with detailed morphologic information and additional insights into metabolism and blood flow with advanced MRI techniques, such as spectroscopy and perfusion. However, MRI still has limitations in identifying tumor type and grade and in detecting diffuse infiltrative growth, treatment-induced changes and recurrences. Additional information can be obtained using positron emission tomography (PET), which provides quantitative information of cellular activity and metabolism. By combining PET and MRI in the recently available hybrid PET/MRI scanners, morphologic, functional, metabolic, and molecular information of the human brain can be obtained simultaneously. 4 and by the European Association of Nuclear Medicine. 2 By adding PET to the common routine MRI examination, it has been demonstrated that the diagnostic accuracy and noninvasive grading of cerebral gliomas improve. [4] [5] [6] [7] [8] [9] PET also represents a powerful tool to identify the metabolically most active intratumoral areas before resection and might prevent histopathologic undergrading. 10 A total PET tracer uptake resection (using [ C-MET) has been associated with significantly longer survival in patients with glioma. 11 A study by Tanaka et al. 12 reported that a navigation system with combined PET ( 11 C-MET) and MRI was more effective in reducing the tumor mass, as well as benefited patient survival, compared with the conventional navigation-guided surgery based on MRI only. Previous studies have also shown that the kinetic behavior of amino acid PET tracers differs between lowand high-grade glioma and that time-activity curves (TACs) could be used to differentiate different types of brain tumors.
13,14
Anti-1-amino-3-[ F-FACBC) is another clinically available synthetic amino acid radiotracer, primarily used for detection of prostate cancer. [15] [16] [17] Although originally developed for brain tumors, 18 only a few studies have been performed with 18 F-fluciclovine in the human brain. These studies demonstrate potential in detection of histopathologic confirmed tumor residuals or recurrences of gliomas, 18, 19 usefulness in therapeutic response evaluation of human gliomas 20 and presurgical glioblastoma evaluation. 21 Results show higher tumor-to-background ratios (TBRs) than for both 11 C-MET and 18 F-FET, 22 which might indicate that 18 Ffluciclovine could be more sensitive than the currently recommended amino acid radiotracers for brain tumor imaging.
Presurgical planning with simultaneous dynamic 18 F-fluciclovine PET/MRI has not been previously reported in glioma patients, and this case study aims to exemplify the value of 18 F-fluciclovine PET in primary staging, diagnosis, surgery, and biopsy of a brain glioma, compared to routine examination with MRI alone. Navigated, image-guided biopsies were taken before tumor resection and PET/MRI image data were related to histopathologic and molecular analysis of these biopsies for validation.
CASE PRESENTATION
A previously healthy 60-year old woman was admitted to the emergency care with speech difficulties and a mild left-side hemiparesis. A stroke was suspected, and CT of the brain showed a hypodense extensive lesion in the right frontal lobe. An MRI examination revealed a 33 Â 46 mm intra-axial tumor with subtle patchy contrast enhancement in the periphery and varying fluid attenuated inversion recovery (FLAIR)-signal within the tumor, suggestive of a diffuse low-grade glioma, possibly with malignant transformation. A brain tumor resection was scheduled. Before surgery, the patient gave informed consent to participate in a study for evaluating the additional value of 18 F-fluciclovine PET in a simultaneous PET/MRI examination. The study was approved by the Regional Ethics Committee (REK, reference number: 2016/279).
PET/MRI Acquisition 18 F-Fluciclovine PET/MRI was acquired on a Siemens Biograph mMR PET/MRI system (Siemens Healthcare, Erlangen, Germany) 2 weeks prior to surgery. MRI was part of the standard diagnostic examination, whereas the simultaneously acquired PET was part of the clinical study. The MRI sequences acquired were pre and post contrast three-dimensional (3D) T1, 3D FLAIR, T2, diffusion, perfusion, and chemical shift imaging (CSI) spectroscopy adhering to the consensus recommendations for brain tumor imaging. 23 An additional ultrashort echo time MRI sequence was acquired for PET attenuation correction.
18 F-Fluciclovine (223. 6 MBq) was administered intravenously at the start of the PET/MRI acquisition and a dynamic/listmode PET acquisition (0e45 minutes post injection) was acquired for the whole brain.
Image Analysis
PET data were reconstructed in 3 Â 15-minute frames, the last 25 minutes and whole acquisition to evaluate optimal acquisition interval, and in 5 Â 1 and 8 Â 5-minute frames to calculate TAC and TBR time dependence. Iterative reconstruction (3D OSEM algorithm, 3 iterations, 21 subsets, 344 Â 344 matrix, 4-mm Gaussian filter) with point spread function, decay, scatter and attenuation correction was employed in the reconstruction of the PET data.
Static PET (20e45 minutes) was used to evaluate standardized uptake values (SUVs) based on patient body weight (SUV bw ). These images were also fused with FLAIR images (OsiriX MD version 8.0.2) and imported into the Sonowand Invite neuro navigational system (Sonowand AS, Trondheim, Norway) together with FLAIR and T1 before surgery.
For dynamic PET data, TAC and TBR were analyzed (GE Advantage Workstation version 4.6) by drawing a manual region of interest (ROI) covering the PET uptake in the tumor and mirrored the region on the contralateral side for background ROI.
The acquired CSI spectroscopy data were analyzed using MATLAB (Mathworks, Natick, MA, USA). The magnetic resonance spectra were fitted using a Voigt curve-fitting algorithm with a confidence limit of R 2 > 0.75 for goodness of fit, as described by Esmaeili et al. 24 Metabolic maps for Choline (Cho)/N-acetylaspartate (NAA) and Cho/Creatinine (Cre) 18 were generated by calculating the area under curves of the fitted metabolites for NAA, Cre and Cho signals voxel-wise. Linear image interpolation was performed on metabolic maps to overlay the CSI-spectroscopy data on the anatomic MRI.
To assess the tumor delineation capability of PET and MRI, the tumor volumes defined by PET (static 20e45 minutes) and MRI was estimated (OsiriX MD version 8.0.2). The PET tumor volume was generated using a threshold of 50% of SUV max within a manually defined ROI. MRI tumor volume was generated by semiautomatic thresholding of the visual FLAIR signal. Clinical PET/MRI was evaluated by an experienced neuroradiologist and a nuclear medicine physician.
Surgery and Histopathological Tissue Sampling
Fused PET/MRI, FLAIR, and T1 images were used together with intraoperative 3D ultrasound acquisitions 25 for multimodal image guidance during biopsy and surgery. Intraoperative ultrasound was acquired at multiple times during surgery due to brain shift, leading to a mismatch between the presurgical MRI and actual brain and tumor localization. Before tumor resection, ultrasound/fused-PET/ MRI localized biopsies were taken from 4 different sites of the tumor. A large (nonlocalized) specimen (35 Â 20 mm) was used for the final histopathologic analysis. All biopsies were diagnosed according to the recent WHO central nervous system classification, including IDH1, 1p/19q, TP53, and ATRX mutation status. In addition, MGMT and TERT promotor methylation status and Ki67 labelling index was obtained. Full description of the histopathological examination is found in Supplementary Material 1. In order to accurately localize the 4 biopsies to the (fused) PET/MRI, the intraoperative 3D ultrasound was nonlinearly registered to the presurgical FLAIR after surgery using Robust PaTchbased cOrrelation Ratio (RaPTOR) algorithm implemented in MATLAB. 26 
RESULTS
PET revealed a lesion localized in the right frontal lobe with high uptake of 18 F-fluciclovine ( Figure 1A) . The uptake was generally highest in the cortex with sparse uptake in the central part of the tumor. The highest uptake was seen in the frontolateral part of the tumor (SUV 1.7). There was also one focal area with uptake medially in the posterior part of the tumor localized toward the falx cerebri (SUV 1.1). The area of reference was placed occipitally with uptake of SUV 0.6. Dynamic PET demonstrated higher TBR for late time frames (Figure 2A) . TAC for the tumor showed a peak during the first minutes, followed by a slight decrease and then a slow increase over time ( Figure 2B ). Background activity in normal brain tissue was constant over time.
The presurgical MRI showed pathologic signal with FLAIR, T1, and T2 sequences (Figures 1BeD) , but without contrast enhancement in any part of the tumor at this examination. Diffusion-weighted MRI showed facilitated diffusion with varying apparent diffusion coefficient (ADC) values across the tumor volume ( Figure 1E ), indicating various cell densities at the different sites. Perfusion showed no pathologic blood flow or volume in any parts of the tumor (compared to the normal brain) ( Figure 1F) . CSI spectroscopy had increased Cho/Cre and Cho/NAA ratios in PET-positive areas (Figures 1GeI) .
The fused PET/MRI images showed uptake of 18 F-fluciclovine in most parts of Table 1 for the large nonlocalized specimen (30 Â 25 mm) and the image-localized biopsies.
Postoperative Outcome
The tumor was resected in total, as judged by the neurosurgeon using the intraoperative ultrasound. There were no perioperative complications or postoperative neurologic deficits. Postoperative MRI was performed within 24 hours, showing total resection of the tumor as judged by the FLAIR-sequence. All tumor with 18 F-fluciclovine-uptake was resected. The patient was then treated with postoperative radiotherapy (1.8 Gy Â 33 fractions) followed by PCV chemotherapy (procarbazine, lomustine, and vincristine). Postoperative MRI at 6 months showed radiation-induced gliosis surrounding the surgical cavity, but no tumor recurrence. The last postoperative MRI currently performed at 12 months did not show any tumor recurrence, and there were no neurologic symptoms at clinical examination.
DISCUSSION

18
F-Fluciclovine uptake in normal brain was low and stable, comparable to other studies using this tracer in glioma evaluation. 19, 21 SUV max and TBR were, however, lower than previously reported. 19, 21, 22 This discrepancy could be due to different glioma grade and subtypes, or recurrences versus primary staging, as the other studies applying 18 Ffluciclovine evaluated residual or recurrent gliomas 19, 22 and presurgical patients with glioblastoma. 21 Furthermore, TBR was in the same range as for other amino acid The dynamic uptake in the tumor demonstrated a peak of 18 F-fluciclovine within the first minutes, followed by a slow activity increase. TBR showed a similar behavior. Kondo et al. 21 demonstrated a slightly different tumor uptake during the first minutes (rapid increase followed by decrease and then steady state within 3 minutes) in patients with glioblastoma, whereas the TBR curve resembled our results. For other amino acid tracers, rapid tumor activity peak followed by decreasing TACs are typically associated with untreated highgrade glioma, while increasing TACs more often occur in low-grade glioma. 13, 14 Kratochwil et al. 32 found that TAC peaked earlier for high-grade gliomas (8 and fluciclovine should be investigated further to evaluate the potential for this radiotracer to differentiate between tumor subtypes and grades.
The total tumor volume defined by FLAIR was larger than the PET-defined tumor volume, and most of the PET defined volume was within the MRIdefined volume. The PET uptake did, however, exceed the MRI-defined volume toward the tumor edges slightly, but this is probably due to partial volume effect in the PET images, caused by limited resolution of the PET system, which makes the activity spill out into the surrounding voxels. 33 In contradiction to our results, Kondo et al. 21 showed that 18 F-fluciclovine has the ability to delineate glioblastoma (grade IV) spread, which was undetectable using MRI. However, they used only contrastenhanced MRI and did not report T2 or FLAIR volumes of the evaluated tumors. In our study, no contrast enhancement was present in the presurgical MRI examination, while the first MRI examination showed patchy contrast enhancement. This difference could be due to different time points after contrast administration for the MRI scans. 34, 35 The lack of contrast enhancement on MRI could suggest that 18 F-fluciclovine PET is a more sensitive method than MRI to detect malignant transformations. It has been shown that tumor progression and malignant transformations may be detected with amino acid PET even before signs of progression are shown by MRI. 36 It is also known that MRI (contrast-enhanced T1, T2, and FLAIR) has limitations in defining viable tumor tissue. Conventional contrastenhanced T1 might not always reflect higher grades of malignancy, 3 and histologic examinations have demonstrated that glioma cells can extend beyond the hyper intense areas shown on T2 images. 37 FLAIR lacks specificity in differentiating between tumor tissue and presence of edema, necrosis, and gliosis. 38 In addition, Zetterling et al. 39 reported tumor cells outside the tumor border delineated on FLAIR. Further studies should be conducted to compare the viable MRIdefined tumor volumes (based on both contrast enhanced MRI and FLAIR) with the PET uptake volume in low-and highgrade gliomas.
In the present case, PET uptake correlated well with the WHO grade, cell density, and Ki67 labeling index. For biopsy A and B, classified as grade II/III with high cell density and high Ki67 labeling index, PET indicated tumor tissue. For biopsy C, classified as grade II with moderate cell density and a lower Ki67 labelling index, PET uptake was just slightly above background, and probably caused by spill-out effect from the 2 hotspots in the surrounding area. For biopsy D, classified as grade II with moderate cell density and lower Ki67 labelling index, there was no increased PET uptake. FLAIR, T1, and T2 on the other hand, were pathologic at all biopsy sites, which also correlates well to the histopathologic results of IDH1, 1p/19q, and TP53. According to the 2016 WHO classification, IDH mutation and 1p/19q codeletion is a prerequisite for diagnosing anaplastic oligodendroglioma, and oligodendrogliomas with IDH mutation and 1p/19q co-deletion rarely harbor TP53 mutations. 40 The histopathologic examination for ATRX, MGMT, and TERT was inconclusive for some of the image-localized biopsies, which makes it difficult to compare to the PET and MRI results.
Taken together, the fused PET/MRI and image-localized biopsy results indicate that 18 F-fluciclovine PET could be suited to detect the most malignant part of gliomas and possibly malignant transformations. This suggests that navigated PET/MRI might prove useful for planning or guiding resections or radiation therapy if targeting merely the most malignant part of extensive and eloquent, but transformed gliomas. The first approach in anaplastic 41 Since most of the PET volume was within the FLAIR volume, the additional PET examination did not change the clinical management of the current patient. Furthermore, a large chunk of the tumor was sent for tissue diagnostics, and undergrading was not a problem (the non-navigated biopsy showed grade III).
ADC-values varied between the different biopsy sites, indicating varying cell density, but there were some inconsistencies when comparing the ADC values with the histopathologic examinations. Biopsy A had high cell density and the lowest ADC value, biopsy D had moderate cell density and the highest ADC value, while for biopsy B and C the results did not correlate.
CSI spectroscopy showed parts of the tumor with increased Cho/Cre and Cho/ NAA ratios compared with normal white matter, as reported previously in malignant gliomas, 42 and these areas also overlapped partly with the PET-positive areas. However, spectroscopy data did not cover the whole tumor and could not be calculated for each biopsy, making it difficult to draw any conclusions regarding the relationship between the CSI and PET uptake.
Ideally, the biopsy sites should have been selected in the middle of PET hotspots and in areas where PET was negative and MRI demonstrated signal. Because of the brain shift that occurs during surgery, it may be difficult to sample biopsies from ideal sites and achieve accurate positions of the biopsies. However, in this case study the biopsies were taken before resection of the tumor, to minimize the impact of brain shift. In addition, during the sampling process in this patient, intraoperative 3D ultrasound images were acquired, which were subsequently registered to the fused PET/MRI images to obtain biopsy positions with high precision post-surgery.
CONCLUSION
MRI delineated the tumor volume better than 18 F-fluciclovine PET in this anaplastic oligodendroglioma WHO grade III tumor. However, PET uptake was highest where tumor grade, cell density, and Ki67 labelling index were highest. This finding indicates that 18 F-fluciclovine PET may harbor potential in detecting the most malignant parts of the tumor and might be more sensitive for detecting malignant transformation than MRI. This may be used to improve accuracy in histopathologic tissue sampling and grading of gliomas, and possibly for guiding treatments targeting the most malignant part of extensive and eloquent gliomas.
